Mission Statement
R&D Pipeline

PBI selectively pursues collaborations to accelerate the commercialization of its pipeline.  The Company also welcomes the opportunity to discuss with potential partners, the ways that its technology can help to create the next breakthrough medicine.

PBI’s BioSynersys™ and ProbioTherapeutic™ platform technologies along with its process know-how are available to partners for the development of next generation therapeutics.  Working with PBI offers access to its unique Synergy PEG reagents. 

In instances where a promising product suffers disappointment after applying conventional Pegylation, a valuable product is limited by the current Pegylation method, or a product encounters any of the problems, such as short half-life, frequent or high dosing, toxicity, immunogenicity, stability, and solubility, PBI is able to offer a solution that could help partners realize the full potential of their products.

Product & Technology Partnership Opportunities

PBI's two core products and BioSynersys™ technology platform are available for partnership opportunities:


PB307 opens up a new realm of anticancer immunotherapy.  PB307 has the potential to be a powerful immune-oncology drug.  In addition to inhibiting tumor growth without drug resistance and adverse effects, the PB307 formula offers other advantages as an immunotherapeutic drug:

· PB307 could be an effective immunotherapeutic drug for prophylaxis of cancer recurrence.

· PB307 has potential to be an anticancer drug with multiple cancer indications, including pancreatic cancer, colorectal cancer, gastric cancer, lung cancer, gastric cancer, head and neck cancer, ovarian cancer, lung cancer, etc.


PB1103, a synergy interferon-alfa, has increased, sustained and prolonged biological activity in blood plasma.  PB1103 is expected to be an effective biotherapy for the treatment of various cancers, including kidney, melanoma, Kaposi sarcoma, hairy cell leukemia (HCL), myeloid leukemia (CML) and hematologic cancers.  PB1103 could be an effective medicine for the treatment of blood diseases, such as polycythaemia vera (PCV), essential thrombocythemia (ET), etc.  PB1103 provides synergistically increased antiviral activity and enhanced pharmacological properties and has been demonstrated to be superior to the commercial Pegylated interferon-alfa in animal studies. 

BioSynersys™ Technology

PBI’s BioSynersys™ technology is available for partnership or licensing for application to biological drugs to develop new generation Synergy PEG-enhanced drugs with the potential to be the next breakthrough therapeutic.

ProbioTherapeutic™ Technology

PBI's ProbioTherapeutic™ technology is a new site-specific conjugation technology that provides (i) retention of 100% activity of biologics in vivo, (ii) increased biologics' bioavailability in blood plasma, (iii) increased solubility of biologics, (iv) improved stability of biologics, and (v) increased half-life of biologics. ProbioTherapeutic™ technology is available for licensing and partnership for application to peptides and biologics to develop improved drug formulations and potentially develop the next breakthrough therapeutics.

Business Development and Partnerships